This phase Ib/II trial evaluates the safety and effect of the Nous-209 vaccine in Lynch syndrome patients. Lynch syndrome is an inherited disorder in which affected individuals have a higher-than-normal chance of developing colorectal cancer and certain other types of cancer, often before the age of 50. In Lynch syndrome, errors in the genetic information inside cells are not properly corrected. When that happens, the cells produce new proteins called neoantigens. Neoantigens are recognized by the body's immune system as foreign, and the body tries to get rid of them. Nous-209 is a vaccine made with man-made copies of some of those neoantigens. This trial aims to see whether the Nous-209 vaccine is safe to give to patients with Lynch syndrome, whether people are able to take the Nous-209 vaccine without becoming too uncomfortable, and how the immune system of patients with Lynch syndrome respond to the Nous-209 vaccine. This trial may help researchers determine whether receiving Nous-209 have an effect on the development of polyps or tumors in the colon.

开始日期2022-11-10

申办/合作机构

National Cancer Institute

NCT04041310 / Recruiting临床1/2期

A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

Ref: Protocol v9.0, dated 7Nov2023. NOUS-209-01 is a multicenter, open-label, multiple cohorts, clinical study, designed to evaluate safety, tolerability, and immunogenicity, and to detect any preliminary evidence of anti-tumor activity of Nous-209 genetic polyvalent vaccine plus pembrolizumab combination therapy in adult subjects with unresectable or metastatic deficient mismatch repair (dMMR) or MSI-H CRC, gastric, or gastro-esophageal junction (G-E junction) tumors. Nous-209 is based on a heterologous prime/boost regimen composed of the Great Ape Adenovirus GAd20-209-FSP used for priming and Modified Vaccinia virus Ankara MVA-209-FSP used for boosting. The Phase I portion of the study is a first-in-human (FIH) clinical study with a primary objective to elucidate the safety and tolerability of Nous-209 in addition to establishing the recommended Phase 2 dose (RP2D), whereas the Phase II was introduced to assess efficacy as the primary objective.

开始日期2019-10-21

申办/合作机构

Nouscom AG初创企业

[+1]

100 项与 MVA-209-FSP 相关的临床结果

登录后查看更多信息

100 项与 MVA-209-FSP 相关的转化医学

登录后查看更多信息

100 项与 MVA-209-FSP 相关的专利（医药）

登录后查看更多信息

项与 MVA-209-FSP 相关的文献（医药）

2020-09-15·Cancer research1区 · 医学

A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability

1区 · 医学

Article

作者: Merone, Rossella ; Mori, Federica ; Troise, Fulvia ; Langone, Francesca ; Yadav, Mahesh ; van der Bruggen, Pierre ; Vanhaver, Cristophe ; Tucci, Fabio Giovanni ; De Lucia, Maria ; Vitale, Rosa ; Folgori, Antonella ; Colloca, Stefano ; D'Alise, Anna Morena ; Ruzza, Valentino ; Catanese, Maria Teresa ; Leuzzi, Adriano ; Nicosia, Alfredo ; Lahm, Armin ; Garzia, Irene ; Di Matteo, Elena ; Bignone, Veronica ; Gordon-Alonso, Monica ; Abbate, Adele ; Diodoro, Maria Grazia ; Soprana, Elisa ; Scarselli, Elisa ; Siccardi, Antonio ; Cotugno, Gabriella ; Fichera, Imma ; Leoni, Guido ; Panigada, Maddalena

Abstract:

Tumors with microsatellite instability (MSI) are caused by a defective DNA mismatch repair system that leads to the accumulation of mutations within microsatellite regions. Indels in microsatellites of coding genes can result in the synthesis of frameshift peptides (FSP). FSPs are tumor-specific neoantigens shared across patients with MSI. In this study, we developed a neoantigen-based vaccine for the treatment of MSI tumors. Genetic sequences from 320 MSI tumor biopsies and matched healthy tissues in The Cancer Genome Atlas database were analyzed to select shared FSPs. Two hundred nine FSPs were selected and cloned into nonhuman Great Ape Adenoviral and Modified Vaccinia Ankara vectors to generate a viral-vectored vaccine, referred to as Nous-209. Sequencing tumor biopsies of 20 independent patients with MSI colorectal cancer revealed that a median number of 31 FSPs out of the 209 encoded by the vaccine was detected both in DNA and mRNA extracted from each tumor biopsy. A relevant number of peptides encoded by the vaccine were predicted to bind patient HLA haplotypes. Vaccine immunogenicity was demonstrated in mice with potent and broad induction of FSP-specific CD8 and CD4 T-cell responses. Moreover, a vaccine-encoded FSP was processed in vitro by human antigen-presenting cells and was subsequently able to activate human CD8 T cells. Nous-209 is an “off-the-shelf” cancer vaccine encoding many neoantigens shared across sporadic and hereditary MSI tumors. These results indicate that Nous-209 can induce the optimal breadth of immune responses that might achieve clinical benefit to treat and prevent MSI tumors.

Significance::

These findings demonstrate the feasibility of an “off-the-shelf” vaccine for treatment and prevention of tumors harboring frameshift mutations and neoantigenic peptides as a result of microsatellite instability.

项与 MVA-209-FSP 相关的新闻（医药）

2024-05-14

·BioSpace

Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Advisor to its Board and Chair of its R&D Committee

Dr. Gallagher, current President of R&D at Syndax Pharmaceuticals and former Chief Medical Officer and Head of Development at AbbVie, brings significant experience of end-to-end development that has resulted in the approval of multiple innovative medicines BASEL, Switzerland – 14th May 2024 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, announces today that Neil Gallagher, MD, PhD, has been appointed as an Independent Advisor to Nouscom’s Board of Directors and will also Chair the Company’s R&D Committee. Dr. Gallagher’s leadership will be essential in guiding Nouscom’s clinical development strategy and activities as it advances its wholly owned clinical pipeline through multiple clinical proof of concept readouts. Dr. Gallagher has over 20 years of experience within large, global pharmaceutical R&D organizations and emerging biopharmaceutical companies. Throughout his career, he has led end-to-end drug development programs that have resulted in the approval of multiple innovative medicines, ranging from small molecules to biologics across several therapeutic areas, including oncology and immunology. Since April 2023, he has served as President of R&D at Syndax Pharmaceuticals, a clinical-stage oncology company developing targeted first-in-class cancer therapies. Prior to this, he led multiple development programs through approval globally and oversaw asset strategy and portfolio management across several therapeutic areas as Chief Medical Officer and Head of Development at AbbVie. Other roles include Head of Global Oncology Development at AbbVie, Head of Development for Oncology and Inflammation at Amgen, and Global Program Head at Novartis Oncology. He has also held clinical development roles at AstraZeneca and Astex Therapeutics. Before entering the industry, Dr. Gallagher received his medical degree from Trinity College, Dublin, and completed his Fellowship in Gynaecological Oncology at the Institute for Cancer Studies, University of Birmingham, UK. Dr. Marina Udier, Chief Executive Officer of Nouscom, commented, “We are thrilled to welcome Neil as Independent Advisor to our Board and Chair of our R&D Committee. His extensive experience and leadership in clinical drug development and registration will provide invaluable insights that will allow us to further accelerate progress across our clinical portfolio of neoantigen-based cancer vaccines, including an ongoing randomized Phase 2 trial of NOUS-209 in MSI colorectal cancer.” Dr. Goran Ando, Independent Chair of Nouscom’s Board, said, “Together with the experience of our existing Board Members, I look forward to Neil’s contributions as Nouscom reports multiple clinical trial readouts and navigates the next exciting steps in its growth.” Dr. Neil Gallagher added, “I am truly excited to be working with Nouscom’s Board and management and look forward to sharing my knowledge and expertise to guide and support the development of its clinical pipeline. Nouscom’s dedication to generating safe, innovative, and potent next-generation cancer immunotherapies that selectively eliminate tumor cells and pre-cancerous lesions could be potentially life-changing for patients and I look forward to helping the Company achieve this.” Ends About Nouscom Nouscom is a clinical-stage immuno-oncology company developing next-generation, off-the-shelf and personalized cancer immunotherapies. Nouscom’s proprietary viral vector platform has the capacity to encode for large payloads of neoantigens or other immunomodulators and clinically demonstrated to safely and potently harness the power of the immune system. Nouscom is currently advancing the clinical development of its wholly owned programs: NOUS-209, an off-the-shelf cancer immunotherapy for the treatment of MSI solid tumors in combination with pembrolizumab in randomized Phase 2 trials. NOUS-209, an off-the-shelf monotherapy in Lynch Syndrome carriers with the potential to ‘intercept cancer’ before it occurs. A Phase 1b is being conducted under a clinical trial collaboration and supply agreement signed in 2022 with the National Cancer Institute (NCI). NOUS-PEV, a personalized cancer immunotherapy, is expected to enter randomized Phase 2 trials in indications with high unmet medical need in 2024. Nouscom has also exclusively out-licensed VAC-85135, an off-the-shelf immunotherapy developed under a multi-project agreement, which is currently under evaluation in a Phase 1 trial for the treatment of Myeloproliferative Neoplasms sponsored by Janssen Research & Development and Bristol Myers Squibb. For more information on Nouscom, please visit the company’s website at or follow us on LinkedIn. Contacts Nouscom Rick Davis, COO E : info@nouscom.com T : +41 61 201 1835 MEDiSTRAVA Sylvie Berrebi, Mark Swallow E : nouscom@medistrava.com T : +44 (0)203 928 6900

临床1期疫苗临床2期免疫疗法高管变更

2024-04-07

·创鉴汇

49家欧洲创新药公司获融资

▎药明康德内容团队编辑欧洲是全球重要医药市场，具有发展成熟、体量庞大、增长稳定的特点。欧洲拥有许多大型医药公司，如德国的拜耳医药、瑞士的罗氏制药、丹麦的诺和诺德及法国的赛诺菲等，并且新锐创新药公司也不断获得投资者的关注。2024年第一季度，至少有49家位于欧洲的创新药公司获得融资，金额总计近9亿美元。值得关注的亮点包括：英国、西班牙、瑞士市场较活跃：英国获融资公司数最多，为18家，西班牙和瑞士均有5家公司获得融资。AI药物公司势头迅猛：获融资公司中，有6家公司利用人工智能辅助进行新药发现，其中利用生成式人工智能技术进行药物发现公司Relation Therapeutics完成了3500万美元种子轮融资。癌症疾病领域为关注重点：23家获融资公司开发疾病领域包含癌症领域，其中值得关注的公司有抗体偶联药物研发公司Tubulis、癌症疫苗研发公司Nouscom、基因疗法研发公司Asgard Therapeutics等。Tubulis完成1.28亿欧元B2轮融资3月15日，Tubulis宣布成功完成了1.28亿欧元的B2轮融资。获得的资金将主要用于支持Tubulis下一代ADC的临床研发，并帮助实现主打候选药物TUB-040和TUB-030的临床概念验证。Tubulis来自德国，正在开发下一代抗体偶联药物（ADCs），通过针对特定靶标定制靶向分子和有效载荷的组合，以开发具有优越性能的新型ADCs。该公司的TUB-040针对肿瘤抗原Napi2b，这是一个在卵巢癌和肺癌中被详细表征的靶标。而TUB-030针对5T4，这是一个在实体瘤中经常过度表达的抗原。这两款候选药物的临床前概念验证数据将在今年四月的美国癌症研究协会（AACR）年会上汇报。Nouscom完成7580万欧元C轮融资3月21日，Nouscom公司宣布完成7580万欧元C轮融资。Nouscom是来自瑞士的一家处于临床阶段的免疫肿瘤学公司，致力于开发以新抗原为靶点、基于病毒载体的现货型和个体化癌症疫苗，旗下主要产品包括针对209个共有新抗原的现货型癌症疫苗NOUS-209以及个体化癌症免疫疗法NOUS-PEV。NOUS-209目前正在随机2期临床试验中进行测试，与帕博利珠单抗联合用于治疗错配修复缺陷/微卫星不稳定（dMMR/MSI）转移性结直肠癌（mCRC）。此外，Nouscom公司已经完成评估NOUS-PEV与检查点抑制剂联合治疗晚期黑色素瘤患者的1b期临床研究，并开展针对具有高度未竟医疗需求适应症的随机2期临床试验。Nouscom公司的现任首席执行官是Marina Udier博士，她曾在诺华公司（Novartis）担任多个高级开发和商务拓展职位，在测试业务和体外诊断领域积累了丰富的经验。Asgard Therapeutics完成3000万欧元A轮融资3月14日，Asgard Therapeutics宣布完成3000万欧元（约合3200万美元）的A轮融资。这些资金将用于支持其主打项目AT-108在2026年前达到支持递交IND申请的状态，扩展和加强其研发团队，并推动新的细胞重编程方式和递送平台，以增强产品管线。Asgard Therapeutics是来自瑞典的一家处于临床前阶段的生物技术公司，致力于在体内直接将细胞重编程用于癌症免疫疗法。公司利用其专有的重编程技术开发基因治疗产品，旨在启动高效的个体化免疫反应。该公司的主要项目AT-108是一种潜在“first-in-class”、现货型基因疗法。AT-108可以将患者体内的癌细胞重编程为常规1型树突状细胞（cDC1s），这是一种稀有的免疫细胞亚群，对于有效的抗肿瘤免疫反应至关重要。这些诱导的cDC1s向免疫系统呈递个体特异性癌症抗原，触发个体化和系统性的抗癌免疫反应。AT-108是基于一种复制缺陷的腺病毒载体疗法，将三种转录因子递送到肿瘤细胞中，重写其基因表达特征，从而将它们重新编程，成为具有免疫原性的cDC1细胞。Aqemia完成3000万欧元A轮融资1月30日，Aqemia宣布完成3000万欧元A轮融资。Aqemia来自法国，致力于药物发现管线的开发，基于量子和统计力学算法生成人工智能来设计新颖的候选药物。该公司的内部管线已经在统计几个正在动物身上进行测试的项目，主要是肿瘤学和免疫肿瘤学，下一阶段的项目将涵盖全方位的治疗领域。据悉，本轮融资将用于加速公司全资药物发现项目和资产管线的增长，并进一步扩大其专有的GenAI和物理药物发现平台。Relation完成3500万美元种子轮融资3月14日，Relation Therapeutics完成了一笔总额为3500万美元的种子轮融资，由Data Collective Venture Capital和英伟达领投。Relation Therapeutics是来自英国的、一家专注于药物开发和转化的公司，以实验和计算系统为核心，利用人工智能（AI）技术加速药物研发。公司通过主动图机器学习结合单细胞分析和深入临床洞察进行药物发现，开创了lab-in-the-loop平台，将主动学习整合到从预测细胞状态到验证新靶点的药物发现的每一步。Relation的机器学习平台能够分析海量的生物医学数据，挖掘出潜在的药物候选者，并预测其疗效和安全性。公司目前聚焦于骨骼相关疾病的研究，开发基于骨质疏松的药物，同时也在研究免疫学和代谢疾病等领域的项目。Stalicla完成1740万美元B轮融资1月16日，来自瑞士的Stalicla宣布完成1740万美元B轮融资。Stalicla致力于推进神经系统疾病的精准医疗管线开发。公司通过其DEPI精准神经平台推进2项治疗自闭症的管线：STP1和STP2。此外，公司建立了STP7 mGluR5负变构调节剂（mGluR5 NAM）平台，以推进药物后期临床开发。据悉，本轮融资将用于推进管线STP1和STP2的临床试验，并加速mGluR5 NAM平台开发。CellVoyant完成760万英镑种子轮融资2月26日，来自英国的CellVoyant宣布完成760万英镑种子轮融资。CellVoyant基于人工智能（AI）技术，致力于为慢性疾病研发新型干细胞疗法。目前业界针对干细胞测量和分化的方法较为缓慢，且对细胞命运决定的实时动态一无所知，导致组织制造方案只能达到次优级。该公司将大规模细胞培养、活细胞成像与由数据驱动的计算机视觉技术相结合，以实时预测和优化细胞命运决定。通过该方法，公司能够发现和控制将干细胞编程为任何期望成体细胞的优秀路径。据悉，本轮融资资金将用于扩大公司业务规模，包括在未来两年内将团队规模扩大一倍、扩大实验室、优化实验基础设施以及进一步开发公司核心人工智能（AI）技术平台。DISCO Pharmaceuticals完成2000万欧元融资1月16日，来自德国的DISCO Pharmaceuticals宣布完成2000万欧元种子轮融资。该公司致力于大规模解锁癌细胞的表面蛋白组（surfaceome），旨在发现新的靶点，并开发潜在“first-in-class”药物。尽管抗体偶联药物（ADCs）和双特异性抗体等生物制品的开发正在快速增长，但目前所有基于抗体的疗法仅靶向不到30个靶点蛋白。公司的表面蛋白组平台能够在癌细胞表面识别蛋白质和蛋白质群体，以可扩展的方式解决了对单特异性和双特异性抗体的潜在新靶点的需求，这使得开发多种癌症特异性疗法成为可能，目前公司已创建了针对小细胞肺癌（SCLC）以及结直肠癌的创新抗癌疗法内部管线。据悉，本轮融资资金将用于公司核心项目的持续性开发。Eisbach完成450万美元新一轮融资3月21日，来自德国的Eisbach宣布完成450万美元新一轮融资。Eisbach是一家临床阶段生物技术公司，专注于开发染色质重组的靶向变构疗法。基于公司搭建的ALLOS药物发现平台，公司开发了药物EIS-12656，目前将要进入1/2期临床试验。这是一种变构小分子抑制剂，针对PARP（DNA修复酶）激活的染色体重塑因子解旋酶ALC1（也称为CHD1L），可通过干扰癌细胞的DNA损伤和修复（DDR）机制来破坏癌细胞生长。据悉，本轮融资将用于支持Eisbach的主要候选药物EIS-12656的1/2期临床试验。读者们请星标⭐创鉴汇，第一时间收到推送免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文由药明康德内容团队根据公开资料整理编辑，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转发/复制至其他平台。转发授权请在「创鉴汇」微信公众号留言联系我们。更多数据内容推荐点击“在看”，分享创鉴汇健康新动态

疫苗AACR会议免疫疗法临床2期抗体药物偶联物

2024-03-21

·BioSpace

Angelini Ventures invests into extended €75.8 million ($82 million) Series C financing round for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer vaccines

Angelini Ventures joins syndicate of top-tier international healthcare investors in Nouscom’s Series C financing round Financing will enable Nouscom to continue advancing the clinical development of its portfolio of neoantigen cancer vaccines to key clinical proof-of-concept endpoints Participation in this financing marks Angelini Ventures’ fourth life sciences investment in 2024 and its 15th since launching its €300 million BioTech and Digital Health fund in 2022 Rome, Italy, 21 March 2024 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions and ideas in BioTech and Digital Health, is pleased to announce its participation in an extension of the Series C financing round for Nouscom, a clinical stage immuno-oncology company based in Basel, Switzerland. Angelini Ventures’ investment of €7 million brings the total raised by Nouscom, in its oversubscribed Series C round – first announced in November 2023 – to €75.8 million (approx. $82 million). Angelini Ventures joins a syndicate of top-tier international healthcare investors through its participation in Nouscom’s financing, including new investors: Andera Partners, Bpifrance (through its InnoBio 2 fund), M Ventures, Revelation Partners, Indaco Venture Partners, Panakès Partners, XGen Ventures; existing investors: 5AM Ventures, EQT Life Sciences, Versant Ventures; and other undisclosed investors. The total proceeds of the Series C financing will enable Nouscom to continue advancing and expanding its wholly owned clinical pipeline to achieve multiple clinical value catalysts including: Readout from its ongoing randomized Phase 2 clinical trial for NOUS-209, an off-the-shelf cancer vaccine for the treatment of Mismatch Repair/Microsatellite Instable (dMMR/MSI) Metastatic Colorectal Cancer (mCRC) Phase 1b study completion and progression of NOUS-209 monotherapy in Lynch Syndrome (LS) carriers investigating the potential to intercept, prevent or delay cancer in high-risk individuals Phase 1b study completion for NOUS-PEV, a personalized cancer immunotherapy, in combination with a checkpoint inhibitor in patients with advanced melanoma and entry into randomized Phase 2 trials in indications with high unmet medical needs. Paolo Di Giorgio, Chief Executive Officer at Angelini Ventures, said: “In less than two years since launching our healthcare focused venture strategy, we have executed 15 global investments spanning biotechnology to digital health. Our aim is to promote innovation by investing in a portfolio of high-quality companies in Europe and North America that are transforming healthcare to improve patient outcomes. Our investment in Nouscom is a great example of the type of company we are interested in. We have been highly impressed with Nouscom’s team, best-in-class technology and advancing clinical pipeline, which is expected to deliver multiple catalysts in the coming years and, if positive, exciting new immunotherapy options for cancer patients.” Dr. Marina Udier, Chief Executive Officer at Nouscom, commented: “We are delighted to have extended our successful Series C financing round and excited to have Angelini Ventures on board. Their support strengthens our commitment to innovation and accelerates our journey towards delivering next-generation treatments for cancer patients.” Sergio Marullo di Condojanni, Chief Executive Officer of Angelini Industries, added: “As shareholders of Angelini Ventures, we look at opportunities that can be interesting not only in terms of return on investment but also to support ideas and new projects able to design high-impact solutions. This kind of investment fully responds to our long-term vision which is to take care of patients, communities, and nations, aiming to transform the future of the global health system.” *** Notes to Editors About Angelini Ventures Angelini Ventures, the venture capital arm of Angelini Industries, is an early-stage investment firm focused on accelerating disruptive innovations and trends in BioTech and Digital Health. The firm will invest €300 million across a global portfolio led by investment professionals and advisors in Europe, North America, and Asia. Angelini Ventures has deep domain expertise and leverages a global team, advisors, and strategic partners to help entrepreneurs scale their businesses into transformative category-leading companies. To date, Angelini Ventures has invested €80 million into 15 companies (five of which were created with Angelini Lumira Biosciences Fund) covering a range of therapeutic areas and modalities, including Cour Pharmaceuticals, Noctrix Health, Avation Medical, Pretzel Therapeutics, Cadence Neuroscience and Freya Biosciences. About Angelini Industries Angelini Industries is a multinational industrial group founded in Ancona in 1919 by Francesco Angelini. Today, Angelini Industries represents a solid and diversified industrial reality that employs approximately 5,800 employees and operates in 21 countries around the world with revenues of over 2 billion euros, generated in the health, industrial technology and consumer goods sectors. A targeted investment strategy for growth, constant commitment to research and development, deep knowledge of markets and business sectors, make Angelini Industries one of the Italian companies of excellence in the sectors in which it operates. About Nouscom Nouscom is a clinical-stage immuno-oncology company developing next-generation, off-the-shelf and personalized cancer immunotherapies. Nouscom’s proprietary viral vector platform has the capacity to encode for large payloads of neoantigens or other immunomodulators and clinically demonstrated to safely and potently harness the power of the immune system. Nouscom is currently advancing the clinical development of its wholly owned programs: NOUS-209, an off-the-shelf cancer immunotherapy for the treatment of MSI solid tumors in combination with pembrolizumab in randomized Phase 2 trials. In January 2023, Nouscom announced a clinical trial collaboration and pembrolizumab supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA). NOUS-209, an off-the-shelf monotherapy in Lynch Syndrome carriers with the potential to ‘intercept cancer’ before it occurs. A Phase 1b is being conducted under a clinical trial collaboration and supply agreement signed in 2022 with the National Cancer Institute (NCI) and a randomized Phase 2 trial is expected to be initiated in 2024. NOUS-PEV, a personalized cancer immunotherapy, is expected to enter randomized Phase 2 trials in indications with high unmet medical need in 2024. Nouscom has also exclusively out-licensed VAC-85135, an off-the-shelf immunotherapy developed under a multi-project agreement, which is currently under evaluation in a Phase 1 trial for the treatment of Myeloproliferative Neoplasms sponsored by Janssen Research & Development and Bristol Myers Squibb. For more information on Nouscom, please visit the company’s website at or follow us on LinkedIn. Contacts Angelini Ventures Paolo Di Giorgio, CEO Martina Palmese, Communications Coordinator martina.palmese@angeliniventures.com SEC Newgate Italia Daniele Pinosa daniele.pinosa@secnewgate.it Tel. +39 3357233872 Fausta Tagliarini fausta.tagliarini@secnewgate.it Tel. +39 3476474513 Daniele Murgia daniele.murgia@secnewgate.it Tel. +39 3384330031 MEDiSTRAVA (for press outside Italy) Sylvie Berrebi, Sandi Greenwood, Mark Swallow Sylvie.berrebi@medistrava.com Nouscom Rick Davis, COO info@nouscom.com

临床2期免疫疗法临床1期疫苗

100 项与 MVA-209-FSP 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
遗传性非息肉病性结直肠癌	临床2期	美国	National Cancer Institute	2022-11-10
遗传性非息肉病性结直肠癌	临床2期	波多黎各	National Cancer Institute	2022-11-10
MSI 癌症	临床1期	美国	Nouscom AG初创企业	2019-10-21
转移性结直肠癌	临床1期	-	Nouscom AG初创企业	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04041310 (NOUS-209-01, ASCO2023) 人工标引	临床1/2期	错配修复缺陷或微高卫星不稳定性结直肠癌一线 Deficient DNA Mismatch Repair (dMMR) \| MSI-High	7	Pembrolizumab+NOUS-209	夢衊艱窪築衊鑰鏇夢積(糧壓糧觸艱鹹壓簾窪衊) = 衊鹹齋築製襯廠夢願顧淵鏇襯齋糧遞繭衊鑰糧 (憲觸願構醖鑰膚構網淵 ) 更多	积极	2023-05-26
NCT04041310 (SITC2022) 人工标引	临床1期	Turcot综合征一线 Deficient DNA Mismatch Repair (dMMR) \| MSI-H	12	pembrolizumab+Nous-209 (dose level 1)	鬱築繭構艱簾襯醖糧遞(廠積鑰繭醖蓋鏇鹹壓衊) = 鬱窪鏇衊膚積範鑰餘觸鑰選壓繭網鑰願襯遞壓 (壓壓獵獵觸範鬱艱願鬱 ) 更多	积极	2022-09-27
NCT04041310 (SITC2022) 人工标引	临床1期	Turcot综合征一线 Deficient DNA Mismatch Repair (dMMR) \| MSI-H	12	pembrolizumab+Nous-209 (dose level 2)	鬱築繭構艱簾襯醖糧遞(廠積鑰繭醖蓋鏇鹹壓衊) = 糧艱築鑰選糧衊選鹹蓋鑰選壓繭網鑰願襯遞壓 (壓壓獵獵觸範鬱艱願鬱 ) 更多	积极	2022-09-27
AACR2022	N/A	MSI 癌症	-	Nous-209	顧艱醖窪醖廠遞夢餘觸(廠簾築觸淵網選製簾糧) = 窪鏇膚窪網艱夢積餘積顧繭觸願觸壓餘廠鏇餘 (獵衊鑰積廠願網網憲願 )	-	2022-06-15
NCT04041310 (ESMO2021) 人工标引	临床1期	Turcot综合征 Deficient DNA Mismatch Repair (dMMR) \| MSI	6	pembrolizumab+Nous-209	遞選選艱鹹壓構製遞築(窪膚憲構觸餘鏇窪範網) = None 繭糧衊廠衊觸鹹簾膚憲 (壓糧獵襯築觸糧艱膚餘 )	积极	2021-09-16